v3.26.1
Segment and Geographical Data
 6 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment and Geographical Data
Note 9 — Segment and Geographical Data
The Company's operations include four product lines which constitute one operating segment engaged in providing solutions to improve the health and well-being of people living with diabetes. The Company's chief operation decision maker ("CODM") is the Chief Executive Officer. The CODM assesses performance and decides how to allocate resources for the Company's one operating segment based on consolidated net income that is reported on the Condensed Consolidated Statements of Income. The Company has also evaluated the significant segment expenses incurred by our single segment that are regularly provided to the CODM. The significant expenses provided to the CODM are consistent with those reported on the Condensed Consolidated Statements of Income and include cost of products sold, selling and administrative expense, research and development, other operating income and expense, interest expense, other income and expense, and income taxes. The CODM uses these metrics to make key operating decisions which include approving the design of key commercialization strategies, decisions about key personnel, and approving annual operating and capital budgets. The CODM considers budget-to-actual variances and year over year performance when making decisions supporting resource allocation. The Company manages assets on a consolidated basis as reported on the Condensed Consolidated Balance Sheets.
Disaggregation of Revenues
The Company has distribution agreements with regional or national distributors (including wholesalers and medical suppliers) to ensure broad availability of its products as well as a direct sales force in certain countries and regions around the world. In the United States and Canada, the Company utilizes its key account managers that call on payers, retailers, wholesalers and institutional customers, and field-based territory managers that call on health care providers and pharmacies. In certain markets within Europe, the Company has dedicated sales representatives and in certain regions of the Middle East and Africa, the Company has distribution agreements. In Asia, the Company has distribution agreements, and in China the Company relies on its own commercial team to support sales execution. In Latin America, the Company maintains distribution agreements and direct sales representatives.
The Company disaggregates its revenue by geography and product line as management believes these categories best depict how the nature, amount, and timing of revenues and cash flows are affected by economic factors.
Revenues by geographic region are as follows:
 Three months ended March 31,Six months ended March 31,
2026202520262025
United States$95.4 $135.2 $226.3 $276.9 
International (1)
126.4 123.8 256.7 244.0 
Total$221.8 $259.0 $483.0 $520.9 
(1)For the three and six months ended March 31, 2026 and 2025, no individual country outside of the United States generated net revenues that represented more than 10.0% of total revenues.
Revenues by product line are as follows:
 Three months ended March 31,Six months ended March 31,
2026202520262025
Pen Needles$154.7 $188.3 $340.2 $379.4 
Syringes26.3 28.8 57.0 57.2 
Safety34.3 34.2 71.6 68.4 
Other (2)
4.0 3.3 7.6 6.7 
Contract Manufacturing2.5 4.4 6.6 9.2 
Total$221.8 $259.0 $483.0 $520.9 
(2)Other includes product sales for swabs and other accessories.